دورية أكاديمية
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
| العنوان: | Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes |
|---|---|
| المؤلفون: | Aroda, Vanita R., Erhan, Umut, Jelnes, Peter, Meier, Juris J., Abildlund, Morten Tind, Pratley, Richard, Vilsbøll, Tina, Husain, Mansoor |
| المصدر: | Aroda , V R , Erhan , U , Jelnes , P , Meier , J J , Abildlund , M T , Pratley , R , Vilsbøll , T & Husain , M 2023 , ' Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes ' , Diabetes, Obesity and Metabolism , vol. 25 , no. 5 , pp. 1385-1397 . https://doi.org/10.1111/dom.14990Test |
| سنة النشر: | 2023 |
| المجموعة: | University of Copenhagen: Research / Forskning ved Københavns Universitet |
| مصطلحات موضوعية: | antidiabetic drug, GLP-1, phase III study, randomized trial, type 2 diabetes |
| الوصف: | Aim Glucagon-like peptide-1 receptor agonists improve glycaemic control: some are now available as oral and subcutaneous formulations, and some have indications for reducing cardiovascular risk. The expanded scope for these therapies warrants comprehensive safety evaluations. We report the safety/tolerability of subcutaneous and oral semaglutide from the SUSTAIN and PIONEER clinical trial programmes, respectively. Materials and methods Adverse events (AEs) from 16 randomized placebo- or active-controlled phase IIIa trials in patients with type 2 diabetes (n = 11 159) including once-weekly subcutaneous semaglutide (n = 3150; SUSTAIN trials) or once-daily oral semaglutide (n = 4116; PIONEER trials) were analysed. Data pools were analysed for each programme, with separate analyses of cardiovascular outcomes trials (CVOTs; n = 6480). Results In the phase IIIa pools, gastrointestinal disorders were reported in 41.9%/39.1% of patients with subcutaneous/oral semaglutide, respectively (most prevalent during initiation/escalation) versus 22.0%/24.8% with comparators. Rates of kidney disorders, acute pancreatitis, malignant neoplasms, hypoglycaemia, diabetic retinopathy, heart failure and other cardiovascular events were similar for semaglutide versus comparators. Cholelithiasis incidence was higher with subcutaneous and oral semaglutide versus placebo. Diabetic retinopathy incidence was higher with subcutaneous semaglutide versus placebo in SUSTAIN 6. Small pulse rate increases occurred with both formulations; there was no increased rate of arrhythmias. Fatal AE incidence was similar between semaglutide and comparators. Versus placebo, CVOTs showed a reduced risk of major adverse cardiovascular events with subcutaneous semaglutide and non-inferiority criteria were met with oral semaglutide. Conclusions The most common AEs with semaglutide were gastrointestinal disorders, which decreased with continued therapy. These comprehensive safety/tolerability data may better inform patient selection and guidance in care. ; Aim: ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1111/dom.14990 |
| الإتاحة: | https://doi.org/10.1111/dom.14990Test https://curis.ku.dk/portal/da/publications/safety-and-tolerability-of-semaglutide-across-the-sustain-and-pioneer-phase-iiia-clinical-trial-programmesTest(6dfb69dc-bb75-47b4-9dee-55ea56059d8f).html https://curis.ku.dk/ws/files/365703618/Diabetes_Obesity_Metabolism_2023_Aroda.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.23FBE518 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/dom.14990 |
|---|